All In Biotech

Drug Trial Radar · NCT03568331

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

A Randomized, Double-Blind, Placebo-Controlled Efficacy Study of The Neurokinin-1 Receptor Antagonist VLY-686 in Patients With Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: May 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 375 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

375

Actual

Start

Jul 9, 2018

Primary completion

Dec 27, 2019

Study completion Dec 27, 2019

Sponsor

Lead sponsor
Vanda PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.

Conditions

  • Atopic Dermatitis

Interventions

  • TradipitantDrug

    Oral Capsule

  • PlaceboDrug

    Oral Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of Worst Itch in Atopic DermatitisTime frame: 8 weeks

Locations

70 sites in 1 country. Site status is shown where the registry gives one.

  • Vanda Investigational Site

    Birmingham, Alabama

  • Vanda Investigational Site

    Birmingham, Alabama

  • Vanda Investigational Site

    Tempe, Arizona

  • Vanda Investigational Site

    Encino, California

  • Vanda Investigational Site

    Fountain Valley, California

  • Vanda Investigational Site

    Fremont, California

  • Vanda Investigational Site

    Laguna Hills, California

  • Vanda Investigational Site

    Lomita, California

  • Vanda Investigational Site

    Long Beach, California

  • Vanda Investigational Site

    Los Angeles, California

  • Vanda Investigational Site

    Los Angeles, California

  • Vanda Investigational Site

    San Diego, California

  • Vanda Investigational Site

    Santa Monica, California

  • Vanda Investigational Site

    Denver, Colorado

  • Vanda Investigational Site

    Aventura, Florida

  • Vanda Investigational Site

    Clearwater, Florida

  • Vanda Investigational Site

    Fort Lauderdale, Florida

  • Vanda Investigational Site

    Hialeah, Florida

  • Vanda Investigational Site

    Miami, Florida

  • Vanda Investigational Site

    Miami, Florida

  • Vanda Investigational Site

    Miramar, Florida

  • Vanda Investigational Site

    Ormond Beach, Florida

  • Vanda Investigational Site

    South Miami, Florida

  • Vanda Investigational Site

    Tampa, Florida

  • Vanda Investigational Site

    Savannah, Georgia

  • Vanda Investigational Site

    Boise, Idaho

  • Vanda Investigational Site

    Normal, Illinois

  • Vanda Investigational Site

    Skokie, Illinois

  • Vanda Investigational Site

    Plainfield, Indiana

  • Vanda Investigational Site

    Crowley, Louisiana

  • Vanda Investigational Site

    Rockville, Maryland

  • Vanda Investigational Site

    Towson, Maryland

  • Vanda Investigational Site

    Beverly, Massachusetts

  • Vanda Investigational Site

    Brighton, Massachusetts

  • Vanda Investigational Site

    Fort Gratiot, Michigan

  • Vanda Investigational Site

    Saint Joseph, Missouri

  • Vanda Investigational Site

    St Louis, Missouri

  • Vanda Investigational Site

    Omaha, Nebraska

  • Vanda Investigational Site

    Las Vegas, Nevada

  • Vanda Investigational Site

    Las Vegas, Nevada

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.